These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38805909)

  • 1. Structural optimization of Moracin M as novel selective phosphodiesterase 4 inhibitors for the treatment of idiopathic pulmonary fibrosis.
    Wang S; Yang G; Zhang K; Chen Z; Qiu M; Hou S; Zheng T; Wu Z; Ma Q; Zhang F; Gao G; Huang YY; Zhou Q; Luo HB; Wu D
    Bioorg Chem; 2024 Aug; 149():107474. PubMed ID: 38805909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mangostanin Derivatives as Novel and Orally Active Phosphodiesterase 4 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis with Improved Safety.
    Huang YY; Deng J; Tian YJ; Liang J; Xie X; Huang Y; Zhu J; Zhu Z; Zhou Q; He X; Luo HB
    J Med Chem; 2021 Sep; 64(18):13736-13751. PubMed ID: 34520193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of Novel Selective and Orally Bioavailable Phosphodiesterase-1 Inhibitors for the Efficient Treatment of Idiopathic Pulmonary Fibrosis.
    Wu Y; Tian YJ; Le ML; Zhang SR; Zhang C; Huang MX; Jiang MY; Zhang B; Luo HB
    J Med Chem; 2020 Jul; 63(14):7867-7879. PubMed ID: 32603117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel pyrrolo[2,1-c][1,4]benzodiazepine-3,11-dione (PBD) derivatives as selective HDAC6 inhibitors for the efficient treatment of idiopathic pulmonary fibrosis (IPF) in vitro and in vivo.
    Li Y; Yang H; Zhao X; Zhao X; Quan J; Wang L; Ma E; Ma C
    Eur J Med Chem; 2024 Sep; 275():116608. PubMed ID: 38905805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BI 1015550: an investigational phosphodiesterase 4B (PDE4B) inhibitor for lung function decline in idiopathic pulmonary fibrosis (IPF).
    Sgalla G; Simonetti J; Cortese S; Richeldi L
    Expert Opin Investig Drugs; 2023 Jan; 32(1):17-23. PubMed ID: 36693635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients.
    Bondue B; Castiaux A; Van Simaeys G; Mathey C; Sherer F; Egrise D; Lacroix S; Huaux F; Doumont G; Goldman S
    Respir Res; 2019 Jan; 20(1):10. PubMed ID: 30646908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel phosphodiesterase 4 inhibitor, AA6216, reduces macrophage activity and fibrosis in the lung.
    Matsuhira T; Nishiyama O; Tabata Y; Kaji C; Kubota-Ishida N; Chiba Y; Sano H; Iwanaga T; Tohda Y
    Eur J Pharmacol; 2020 Oct; 885():173508. PubMed ID: 32858049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of TGF-β1/Smad3 signaling by compound 5aa: A potential treatment for idiopathic pulmonary fibrosis.
    An B; Fang Y; Wang L; Nie W; Wang M; Nie H; Wu C; Wang R
    Bioorg Chem; 2024 Jun; 147():107374. PubMed ID: 38636433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphodiesterase 4 inhibition reduces lung fibrosis following targeted type II alveolar epithelial cell injury.
    Sisson TH; Christensen PJ; Muraki Y; Dils AJ; Chibucos L; Subbotina N; Tohyama K; Horowitz JC; Matsuo T; Bailie M; Nikam S; Hazama M
    Physiol Rep; 2018 Jun; 6(12):e13753. PubMed ID: 29952109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of CHIT1 as a novel therapeutic approach in idiopathic pulmonary fibrosis.
    Sklepkiewicz P; Dymek BA; Mlacki M; Koralewski R; Mazur M; Nejman-Gryz P; Korur S; Zagozdzon A; Rymaszewska A; von der Thüsen JH; Siwińska AM; Güner NC; Cheda Ł; Paplinska-Goryca M; Proboszcz M; van den Bosch TPP; Górska K; Golab J; Kamiński RM; Krenke R; Golebiowski A; Dzwonek K; Dobrzanski P
    Eur J Pharmacol; 2022 Mar; 919():174792. PubMed ID: 35122869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and Optimization of α-Mangostin Derivatives as Novel PDE4 Inhibitors for the Treatment of Vascular Dementia.
    Liang J; Huang YY; Zhou Q; Gao Y; Li Z; Wu D; Yu S; Guo L; Chen Z; Huang L; Liang SH; He X; Wu R; Luo HB
    J Med Chem; 2020 Mar; 63(6):3370-3380. PubMed ID: 32115956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages.
    Maier C; Ramming A; Bergmann C; Weinkam R; Kittan N; Schett G; Distler JHW; Beyer C
    Ann Rheum Dis; 2017 Jun; 76(6):1133-1141. PubMed ID: 28209630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Saracatinib, a Selective Src Kinase Inhibitor, Blocks Fibrotic Responses in Preclinical Models of Pulmonary Fibrosis.
    Ahangari F; Becker C; Foster DG; Chioccioli M; Nelson M; Beke K; Wang X; Justet A; Adams T; Readhead B; Meador C; Correll K; Lili LN; Roybal HM; Rose KA; Ding S; Barnthaler T; Briones N; DeIuliis G; Schupp JC; Li Q; Omote N; Aschner Y; Sharma L; Kopf KW; Magnusson B; Hicks R; Backmark A; Dela Cruz CS; Rosas I; Cousens LP; Dudley JT; Kaminski N; Downey GP
    Am J Respir Crit Care Med; 2022 Dec; 206(12):1463-1479. PubMed ID: 35998281
    [No Abstract]   [Full Text] [Related]  

  • 14. Advances in the Development of Phosphodiesterase-4 Inhibitors.
    Peng T; Qi B; He J; Ke H; Shi J
    J Med Chem; 2020 Oct; 63(19):10594-10617. PubMed ID: 32255344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochanin-A ameliorates pulmonary fibrosis by suppressing the TGF-β mediated EMT, myofibroblasts differentiation and collagen deposition in in vitro and in vivo systems.
    Andugulapati SB; Gourishetti K; Tirunavalli SK; Shaikh TB; Sistla R
    Phytomedicine; 2020 Nov; 78():153298. PubMed ID: 32781391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
    Finnerty JP; Ponnuswamy A; Dutta P; Abdelaziz A; Kamil H
    BMC Pulm Med; 2021 Dec; 21(1):411. PubMed ID: 34895203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and biological evaluation of tetrahydroisoquinolines derivatives as novel, selective PDE4 inhibitors for antipsoriasis treatment.
    Zhang R; Li H; Zhang X; Li J; Su H; Lu Q; Dong G; Dou H; Fan C; Gu Z; Mu Q; Tang W; Xu Y; Liu H
    Eur J Med Chem; 2021 Feb; 211():113004. PubMed ID: 33218684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of the novel Benzo[b]thiophene 1,1-dioxide derivatives as a potent STAT3 inhibitor against idiopathic pulmonary fibrosis.
    Wang Y; Liu H; Li W; Xie Y; Gan C; Xue T; Su X; Yue L; Wang Q; Fan C; Zhang Y; Ye T
    Eur J Med Chem; 2023 Jan; 246():114953. PubMed ID: 36463728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual inhibition of α
    Decaris ML; Schaub JR; Chen C; Cha J; Lee GG; Rexhepaj M; Ho SS; Rao V; Marlow MM; Kotak P; Budi EH; Hooi L; Wu J; Fridlib M; Martin SP; Huang S; Chen M; Muñoz M; Hom TF; Wolters PJ; Desai TJ; Rock F; Leftheris K; Morgans DJ; Lepist EI; Andre P; Lefebvre EA; Turner SM
    Respir Res; 2021 Oct; 22(1):265. PubMed ID: 34666752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of mast cells: a novel mechanism by which nintedanib may elicit anti-fibrotic effects.
    Overed-Sayer C; Miranda E; Dunmore R; Liarte Marin E; Beloki L; Rassl D; Parfrey H; Carruthers A; Chahboub A; Koch S; Güler-Gane G; Kuziora M; Lewis A; Murray L; May R; Clarke D
    Thorax; 2020 Sep; 75(9):754-763. PubMed ID: 32709610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.